img

Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Research Report 2024

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age.
According to MRAResearch’s new survey, global Polycystic Ovarian Syndrome (PCOS) Therapeutics market is projected to reach US$ 4636.6 million in 2033, increasing from US$ 3740.4 million in 2022, with the CAGR of 3.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Polycystic Ovarian Syndrome (PCOS) Therapeutics market research.
Key companies engaged in the Polycystic Ovarian Syndrome (PCOS) Therapeutics industry include Bristol Myers Squibb, Crinetics Pharmaceuticals, Inc., EffRx, Inc., Ferring Pharmaceuticals, Merck KGaA, Neurocrine Biosciences, Inc., Novartis Pharmaceuticals, Pfizer Inc. and Sanofi Aventis, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Polycystic Ovarian Syndrome (PCOS) Therapeutics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Polycystic Ovarian Syndrome (PCOS) Therapeutics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Polycystic Ovarian Syndrome (PCOS) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Bristol Myers Squibb
Crinetics Pharmaceuticals, Inc.
EffRx, Inc.
Ferring Pharmaceuticals
Merck KGaA
Neurocrine Biosciences, Inc.
Novartis Pharmaceuticals
Pfizer Inc.
Sanofi Aventis
Teva Pharmaceutical Industries Limited
Segment by Type
Oral Contraceptive
Ovulation Inducing Agents
Facial Hair Growth Inhibitor
Insulin Sensitizing Agent

Segment by Application


Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Polycystic Ovarian Syndrome (PCOS) Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Oral Contraceptive
1.2.3 Ovulation Inducing Agents
1.2.4 Facial Hair Growth Inhibitor
1.2.5 Insulin Sensitizing Agent
1.3 Market by Application
1.3.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Perspective (2018-2033)
2.2 Polycystic Ovarian Syndrome (PCOS) Therapeutics Growth Trends by Region
2.2.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Polycystic Ovarian Syndrome (PCOS) Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Region (2024-2033)
2.3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Dynamics
2.3.1 Polycystic Ovarian Syndrome (PCOS) Therapeutics Industry Trends
2.3.2 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Drivers
2.3.3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Challenges
2.3.4 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Players by Revenue
3.1.1 Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue
3.4 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Concentration Ratio
3.4.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue in 2022
3.5 Polycystic Ovarian Syndrome (PCOS) Therapeutics Key Players Head office and Area Served
3.6 Key Players Polycystic Ovarian Syndrome (PCOS) Therapeutics Product Solution and Service
3.7 Date of Enter into Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Polycystic Ovarian Syndrome (PCOS) Therapeutics Breakdown Data by Type
4.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Type (2024-2033)
5 Polycystic Ovarian Syndrome (PCOS) Therapeutics Breakdown Data by Application
5.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2018-2033)
6.2 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2018-2023)
6.4 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2018-2033)
7.2 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2018-2023)
7.4 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2018-2033)
8.2 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2018-2033)
9.2 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2018-2033)
10.2 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Detail
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.1.4 Bristol Myers Squibb Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
11.1.5 Bristol Myers Squibb Recent Development
11.2 Crinetics Pharmaceuticals, Inc.
11.2.1 Crinetics Pharmaceuticals, Inc. Company Detail
11.2.2 Crinetics Pharmaceuticals, Inc. Business Overview
11.2.3 Crinetics Pharmaceuticals, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.2.4 Crinetics Pharmaceuticals, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
11.2.5 Crinetics Pharmaceuticals, Inc. Recent Development
11.3 EffRx, Inc.
11.3.1 EffRx, Inc. Company Detail
11.3.2 EffRx, Inc. Business Overview
11.3.3 EffRx, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.3.4 EffRx, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
11.3.5 EffRx, Inc. Recent Development
11.4 Ferring Pharmaceuticals
11.4.1 Ferring Pharmaceuticals Company Detail
11.4.2 Ferring Pharmaceuticals Business Overview
11.4.3 Ferring Pharmaceuticals Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.4.4 Ferring Pharmaceuticals Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
11.4.5 Ferring Pharmaceuticals Recent Development
11.5 Merck KGaA
11.5.1 Merck KGaA Company Detail
11.5.2 Merck KGaA Business Overview
11.5.3 Merck KGaA Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.5.4 Merck KGaA Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
11.5.5 Merck KGaA Recent Development
11.6 Neurocrine Biosciences, Inc.
11.6.1 Neurocrine Biosciences, Inc. Company Detail
11.6.2 Neurocrine Biosciences, Inc. Business Overview
11.6.3 Neurocrine Biosciences, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.6.4 Neurocrine Biosciences, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
11.6.5 Neurocrine Biosciences, Inc. Recent Development
11.7 Novartis Pharmaceuticals
11.7.1 Novartis Pharmaceuticals Company Detail
11.7.2 Novartis Pharmaceuticals Business Overview
11.7.3 Novartis Pharmaceuticals Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.7.4 Novartis Pharmaceuticals Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
11.7.5 Novartis Pharmaceuticals Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Detail
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.8.4 Pfizer Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
11.8.5 Pfizer Inc. Recent Development
11.9 Sanofi Aventis
11.9.1 Sanofi Aventis Company Detail
11.9.2 Sanofi Aventis Business Overview
11.9.3 Sanofi Aventis Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.9.4 Sanofi Aventis Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
11.9.5 Sanofi Aventis Recent Development
11.10 Teva Pharmaceutical Industries Limited
11.10.1 Teva Pharmaceutical Industries Limited Company Detail
11.10.2 Teva Pharmaceutical Industries Limited Business Overview
11.10.3 Teva Pharmaceutical Industries Limited Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Limited Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
11.10.5 Teva Pharmaceutical Industries Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Oral Contraceptive
Table 3. Key Players of Ovulation Inducing Agents
Table 4. Key Players of Facial Hair Growth Inhibitor
Table 5. Key Players of Insulin Sensitizing Agent
Table 6. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Region (2018-2023)
Table 10. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Region (2024-2033)
Table 12. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Trends
Table 13. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Drivers
Table 14. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Challenges
Table 15. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Restraints
Table 16. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Players (2018-2023)
Table 18. Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics as of 2022)
Table 19. Ranking of Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Polycystic Ovarian Syndrome (PCOS) Therapeutics Product Solution and Service
Table 23. Date of Enter into Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Type (2018-2023)
Table 27. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Type (2024-2033)
Table 29. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Application (2018-2023)
Table 31. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Application (2024-2033)
Table 33. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 48. Bristol Myers Squibb Company Detail
Table 49. Bristol Myers Squibb Business Overview
Table 50. Bristol Myers Squibb Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 51. Bristol Myers Squibb Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023) & (US$ Million)
Table 52. Bristol Myers Squibb Recent Development
Table 53. Crinetics Pharmaceuticals, Inc. Company Detail
Table 54. Crinetics Pharmaceuticals, Inc. Business Overview
Table 55. Crinetics Pharmaceuticals, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 56. Crinetics Pharmaceuticals, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023) & (US$ Million)
Table 57. Crinetics Pharmaceuticals, Inc. Recent Development
Table 58. EffRx, Inc. Company Detail
Table 59. EffRx, Inc. Business Overview
Table 60. EffRx, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 61. EffRx, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023) & (US$ Million)
Table 62. EffRx, Inc. Recent Development
Table 63. Ferring Pharmaceuticals Company Detail
Table 64. Ferring Pharmaceuticals Business Overview
Table 65. Ferring Pharmaceuticals Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 66. Ferring Pharmaceuticals Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023) & (US$ Million)
Table 67. Ferring Pharmaceuticals Recent Development
Table 68. Merck KGaA Company Detail
Table 69. Merck KGaA Business Overview
Table 70. Merck KGaA Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 71. Merck KGaA Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023) & (US$ Million)
Table 72. Merck KGaA Recent Development
Table 73. Neurocrine Biosciences, Inc. Company Detail
Table 74. Neurocrine Biosciences, Inc. Business Overview
Table 75. Neurocrine Biosciences, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 76. Neurocrine Biosciences, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023) & (US$ Million)
Table 77. Neurocrine Biosciences, Inc. Recent Development
Table 78. Novartis Pharmaceuticals Company Detail
Table 79. Novartis Pharmaceuticals Business Overview
Table 80. Novartis Pharmaceuticals Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 81. Novartis Pharmaceuticals Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023) & (US$ Million)
Table 82. Novartis Pharmaceuticals Recent Development
Table 83. Pfizer Inc. Company Detail
Table 84. Pfizer Inc. Business Overview
Table 85. Pfizer Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 86. Pfizer Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023) & (US$ Million)
Table 87. Pfizer Inc. Recent Development
Table 88. Sanofi Aventis Company Detail
Table 89. Sanofi Aventis Business Overview
Table 90. Sanofi Aventis Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 91. Sanofi Aventis Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023) & (US$ Million)
Table 92. Sanofi Aventis Recent Development
Table 93. Teva Pharmaceutical Industries Limited Company Detail
Table 94. Teva Pharmaceutical Industries Limited Business Overview
Table 95. Teva Pharmaceutical Industries Limited Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 96. Teva Pharmaceutical Industries Limited Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023) & (US$ Million)
Table 97. Teva Pharmaceutical Industries Limited Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Type: 2022 VS 2033
Figure 3. Oral Contraceptive Features
Figure 4. Ovulation Inducing Agents Features
Figure 5. Facial Hair Growth Inhibitor Features
Figure 6. Insulin Sensitizing Agent Features
Figure 7. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Application: 2022 VS 2033
Figure 9. Hospitals Case Studies
Figure 10. Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Polycystic Ovarian Syndrome (PCOS) Therapeutics Report Years Considered
Figure 13. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Region: 2022 VS 2033
Figure 16. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Players in 2022
Figure 17. Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue in 2022
Figure 19. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Country (2018-2033)
Figure 21. United States Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Country (2018-2033)
Figure 25. Germany Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Region (2018-2033)
Figure 33. China Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Country (2018-2033)
Figure 41. Mexico Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Country (2018-2033)
Figure 45. Turkey Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Bristol Myers Squibb Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
Figure 48. Crinetics Pharmaceuticals, Inc. Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
Figure 49. EffRx, Inc. Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
Figure 50. Ferring Pharmaceuticals Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
Figure 51. Merck KGaA Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
Figure 52. Neurocrine Biosciences, Inc. Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
Figure 53. Novartis Pharmaceuticals Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
Figure 54. Pfizer Inc. Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
Figure 55. Sanofi Aventis Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
Figure 56. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed